This study was a prospective, multicenter, non-interventional, real-world study. The study will be divided into two cohorts: Cohort 1 is the younger cohort (aged ≥ 18 and \< 60 years at the start of treatment); Cohort 2 is the older cohort (aged ≥ 60 years at the start of treatment). Patients in this study will receive obinutuzumab-contained regimens according to the investigators' clinical opinion.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: Age ≥ 18 years at the start of treatment;
Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
Previously untreated or relapsed or refractory patients;
Patients who started treatment with otuzumab between June 2021 and April 2023.
You may not be if
Patients currently participating or planning to participate in any interventional clinical trial;
Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.